- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04932980
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD (SPARROW)
April 23, 2024 updated by: Berner Augenklinik
Study Comparing Early Extension of Aflibercept and Brolucizumab in Wet AMD (SPARROW)
The currently widely established and preferred protocol for the treatment of wet age-related macular degeneration includes a loading phase of three monthly injections without interim adaptation or treatment according to disease activity, thereafter following a T&E strategy with treatment adaptation in increments of 2-4 weeks according to disease activity.
Based on pharmacological considerations regarding the vitreal half-life of the drugs, the aim of this prospective explorative study is to test whether an early extension of treatment intervals without a loading phase is an option without compromising functional outcomes.
Based on a superiority of Afl compared to Ran with regard to achieving a dry retina after one year and based on studies, but in the absence of real-life experience with Bro, it seems of interest to test how far Afl and Bro are comparable in terms of their potential to extend the treatment intervals over 12 months, the time to dryness of the retina, and number of injections.
Also, it is of high clinical relevance to demonstrate efficacy with longer initial treatment intervals compared to the current possibly over-treating loading-phase with three four-weekly injections.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bern, Switzerland, 3007
- Berner Augenklinik
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Active MNV secondary to nAMD, going along with clinically significant vision loss
- Patients aged 50 years or older of all sexes
- Presence of IRF and/or SRF and/or subretinal hyperreflective material affecting the central subfield of the study eye on OCT
- signed informed consent for this study prior to the screening visit
- If possible: availability of a smartphone and willingness to perform self-testing with the Alleye app (soft criteria)
Exclusion Criteria:
- Any other cause of macular oedema
- Structural damage to the macula precluding a visual potential
- Optical media opacities not allowing an accurate performance of the protocol examinations
- Any intraocular surgery within three months prior to inclusion and history of any vitreoretinal surgery
- Advanced diabetic retinopathy potentially requiring any treatment within six months following inclusion or history of vitreal haemorrhage
- Presence of vitreoretinal traction or tractive epiretinal membrane affecting the fovea
- History of IVT with anti-VEGF or corticosteroids at any time in the study eye
- Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.
- Significantly worse functional prognosis in the other eye or only eye
- Women of childbearing potential not willing to use an effective method of contraception during treatment and until at least 3 months after the last treatment
- Pregnant or lactating women
- Any systemic auto-inflammatory and auto-immune disease requiring treatment
- Treatment with high-dose corticosteroids (Prednisone equivalent >5mg/day), immunosuppressive or immunomodulatory or anti-proliferative agents for any reason
- Inability or contraindications to undergo the investigated intervention
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aflibercept ® rapid treatment extension (T&E)
Early treat and extend (T&E) with Aflibercept ®.
First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval).
Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.
|
administration of anti-VEGF Aflibercept (Eylea)
extension of treatment intervals (T&E) from the beginning of treatment
|
Active Comparator: Brolucizumab ® rapid treatment extension (T&E)
Early treat and extend (T&E) with Brolucizumab ®.
First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval).
Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.
|
extension of treatment intervals (T&E) from the beginning of treatment
administration of anti-VEGF Brolucizumab (Beovu)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of injections given until week 52
Time Frame: 52 weeks
|
number injections received by patient
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Injections until week 104
Time Frame: 104 weeks
|
number injections received by patient
|
104 weeks
|
Number of treatment failures
Time Frame: 52 weeks
|
number with treatment demand of less than 6 weeks at any time point
|
52 weeks
|
Number of treatment failures
Time Frame: 104 weeks
|
number with treatment demand of less than 6 weeks at any time point
|
104 weeks
|
Time until drying of retina
Time Frame: 52 weeks
|
mean interval until absence of intra- and subretinal fluid
|
52 weeks
|
Time until drying of retina
Time Frame: 104 weeks
|
mean interval until absence of intra- and subretinal fluid
|
104 weeks
|
portion of eyes without disease activity
Time Frame: 52 weeks
|
% patients with absence of intra- and subretinal fluid
|
52 weeks
|
portion of eyes without disease activity
Time Frame: 104 weeks
|
% patients with absence of intra- and subretinal fluid
|
104 weeks
|
eyes under treatment intervals of ≥12 weeks
Time Frame: 52 weeks
|
portion of eyes with stable disease under treatment intervals of ≥12 weeks
|
52 weeks
|
eyes under treatment intervals of ≥12 weeks
Time Frame: 104 weeks
|
portion of eyes with stable disease under treatment intervals of ≥12 weeks
|
104 weeks
|
Change in visual acuity
Time Frame: 52 weeks
|
change of VA in logRAD from baseline to week 52
|
52 weeks
|
Change in visual acuity
Time Frame: 104 weeks
|
change of VA in logRAD from baseline to week 104
|
104 weeks
|
Change in central subfield thickness (CST)
Time Frame: 52 weeks
|
change from baseline to week 52
|
52 weeks
|
Change in central subfield thickness (CST)
Time Frame: 104 weeks
|
change from baseline to week 104
|
104 weeks
|
Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters
Time Frame: 52 weeks
|
change from baseline to week 52
|
52 weeks
|
Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters
Time Frame: 104 weeks
|
change from baseline to week 104
|
104 weeks
|
Maximal treatment interval extension
Time Frame: 52 weeks
|
mean treatment interval extension
|
52 weeks
|
Maximal treatment interval extension
Time Frame: 104 weeks
|
mean treatment interval extension
|
104 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Justus G. Garweg, Prof. Dr. med., Berner Augenklinik
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014 Sep;158(3):532-6. doi: 10.1016/j.ajo.2014.05.025. Epub 2014 May 28.
- Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2181-2192. doi: 10.1007/s00417-020-05048-1. Epub 2021 Feb 2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 9, 2022
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
March 1, 2028
Study Registration Dates
First Submitted
June 6, 2021
First Submitted That Met QC Criteria
June 18, 2021
First Posted (Actual)
June 21, 2021
Study Record Updates
Last Update Posted (Actual)
April 24, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPARROW 2021-01236
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wet Age-related Macular Degeneration
-
Sam Chun Dang Pharm. Co. Ltd.CompletedNeovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
-
AbbVieCompletedWet Macular Degeneration | Neovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States
-
AbbVieAbbVieEnrolling by invitationGene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMDUnited States
-
Novartis PharmaceuticalsWithdrawnWet Age-related Macular Degeneration (Wet AMD)
-
REGENXBIO Inc.CompletedNeovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
Clinical Trials on Aflibercept
-
Regeneron PharmaceuticalsSanofiCompletedSolid TumorsUnited States, Canada
-
CR-CSSS Champlain-Charles-Le MoyneSanofi; Regeneron Pharmaceuticals; Quebec Clinical Research Organization in CancerTerminatedMetastatic Colorectal CancerCanada
-
Samsung Bioepis Co., Ltd.CompletedNeovascular Age-related Macular DegenerationCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
-
Alvotech Swiss AGActive, not recruitingNeovascular (Wet) AMDSlovakia, Czechia, Georgia, Japan, Latvia
-
Bioeq GmbHCompletedNeovascular Age-related Macular DegenerationBulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
-
Regeneron PharmaceuticalsBayerCompletedNeovascular (Wet) Age-Related Macular DegenerationUnited States, Puerto Rico
-
Regeneron PharmaceuticalsBayerActive, not recruitingType 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes MellitusUnited States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary
-
Instituto de Olhos de GoianiaCompleted
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms | Cancer of the OvaryUnited States, France, Canada, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland
-
SanofiRegeneron PharmaceuticalsCompletedOvarian NeoplasmsUnited States, Italy, Sweden